An analysis of outcomes for older patients with plasma cell myeloma suggests lenalidomide with bortezomib and dexamethasone is superior to doublet regimens.
Immunomodulatory imide drug (IMiD) therapy, including thalidomide and lenalidomide, has been associated with a high risk of VTE in patients with NDMM.
The triplet regimen resulted in an 18% reduction in risk for death.
The inclusion of daratumumab in multiple myeloma regimens may be linked to better progression-free survival.
Multiple myeloma trials appear to underrepresent racial minorities in enrollment and in reporting, with no obvious improvement in recent years.
The superiority of carfilzomib vs bortezomib in triplet therapy was compared in newly diagnosed multiple myeloma ineligible for immediate transplantation.
The BLA is supported by data from the open-label, single-arm phase 2 KarMMa study.
An observational study determined that 90-minute rapid infusions of daratumumab for RRMM was safe and well-tolerated.
More data is needed to determine whether newer treatments are truly improving outcomes among patients with r/r multiple myeloma.
Researchers assessed the effects of adding daratumumab to standard frontline induction therapy to treat MM in newly diagnosed, transplant-eligible patients.
